Your browser doesn't support javascript.
loading
Clinical research progress on drugs against SARS-CoV-2 / 中国生物制品学杂志
Chinese Journal of Biologicals ; (12): 469-2023.
Artigo em Chinês | WPRIM | ID: wpr-976180
ABSTRACT
@#The rapid spread of Coronavirus Disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection has had a devastating impact on public health and the global economy. Tremendous efforts had been put on urgent development of prophylactic or therapeutic drugs against SARS-CoV-2,mainly smallmolecule antiviral drugs and monoclonal antibodies,to reduce the impact and burden of COVID-19. Currently,National Medical Products Administration(NMPA)of China or Food and Drug Administration(FDA)of the United States have approved three small-molecule drugs and three monoclonal antibodies for use. This paper reviews the clinical research progress and challenges of the main drugs against SARS-CoV-2 on the market at present.

Buscar no Google
Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Chinese Journal of Biologicals Ano de publicação: 2023 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Buscar no Google
Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Chinese Journal of Biologicals Ano de publicação: 2023 Tipo de documento: Artigo